Pancreatic ductal
adenocarcinoma (PDAC) has a devastating prognosis without effective treatment options. Thus, there is an urgent need for more effective and safe
therapies. Here, inorganic-organic hybrid nanoparticles (GMP-IOH-NPs) are presented as a novel drug-delivery system for the selective delivery of extraordinarily high concentrations of
gemcitabine monophosphate (GMP), not only to the primary
tumor but also to metastatic sites. GMP-IOH-NPs have a composition of [ZrO]2+ [GMP]2 - with GMP as
drug anion (76% of total IOH-NP mass). Multiscale fluorescence imaging confirms an efficient uptake in
tumor cells, independent of the activity of the human-equilibrative-
nucleoside transporter (hENT1), being responsible for
gemcitabine (GEM) transport into cells and a key factor for GEM resistance. Delivering already phosphorylated GMP via GMP-IOH-NPs into
tumor cells also allows the cellular resistance induced by the downregulation of
deoxycytidine kinase to be overcome. GMP-IOH-NPs show high accumulation in
tumor lesions and only minor liver trapping when given intraperitoneally. GMP-IOH-NPs result in a higher antitumor efficacy compared to free GEM, which is further enhanced applying
cetuximab-functionalized GMP-CTX-IOH-NPs. By maximizing the therapeutic benefits with high
drug load,
tumor-specific delivery, minimizing undesired side effects, overcoming mechanisms of chemoresistance, and preventing systemic GEM inactivation, GMP-IOH-NPs are anticipated to have a high chance to significantly improve current PDAC-patient outcome.